PMID- 37114144
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230430
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2023
DP  - 2023
TI  - Antiobesity Effect of Lacticaseibacillus paracasei LM-141 on High-Fat 
      Diet-Induced Rats through Alleviation of Inflammation and Insulin Resistance.
PG  - 1011591
LID - 10.1155/2023/1011591 [doi]
LID - 1011591
AB  - In this study, we set out to evaluate the antiobesity activities of our newly 
      isolated Lacticaseibacillus paracasei LM-141 (LPLM141) using a high-fat diet 
      (HFD)-fed rat model. Male Sprague-Dawley rats were fed with a HFD with or without 
      low-dosage (2 x 10(7) CFU/day per rat) or high-dosage (2 x 10(9) CFU/day per rat) 
      LPLM141 for 14 weeks. The results showed that administration of LPLM141 
      significantly decreased body weight gain, liver weight, adipose tissue weight, 
      and epididymal white adipocyte size increased by HFD feeding. The abnormal serum 
      lipid profile induced by HFD feeding was normalized by administration of LPLM141. 
      The enhanced chronic low-grade inflammation in HFD-fed rats was reduced by 
      LPLM141 supplementation, as reflected by decreased serum lipopolysaccharide (LPS) 
      and monocyte chemoattractant protein-1 (MCP-1) levels, reduced macrophage 
      infiltration in adipose tissue, and increased serum adiponectin concentration. In 
      addition, the elevations of proinflammatory cytokine genes and suppression of 
      PPAR-gamma mRNA in adipose tissues of rats fed with a HFD were markedly reversed by 
      LPLM141 administration. Oral administration of LPLM141 induced browning of 
      epididymal white adipose tissue (eWAT) and activation of interscapular brown 
      adipose tissue (iBAT) in rats fed with HFD. Consumption of LPLM141 exhibited a 
      significant amelioration in insulin resistance, which were mechanistically caused 
      by downregulation of the serum leptin level and upregulation of hepatic IRS-1 and 
      p-Akt protein expressions, in HFD treated rats. LPLM141 consumption significantly 
      decreased hepatic lipogenic gene expressions and preserved liver function 
      stimulated by HFD treatment. Administration of LPLM141 obviously mitigated 
      hepatic steatosis observed in HFD feeding rats. Our current findings shed light 
      on LPLM141 supplementation that exhibited an antiobesity effect in HFD-fed rats 
      by alleviating inflammation and insulin resistance, which further highlighted the 
      potential of utilizing LPLM141 as a preventive/therapeutic probiotic agent for 
      obesity.
CI  - Copyright (c) 2023 Ching-Shuang Wu et al.
FAU - Wu, Ching-Shuang
AU  - Wu CS
AUID- ORCID: 0000-0002-8382-2004
AD  - Department of Medical Laboratory Science and Biotechnology, Kaohsiung Medical 
      University, Kaohsiung 80708, Taiwan.
AD  - Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung 
      80708, Taiwan.
FAU - Lin, Chih-Chieh
AU  - Lin CC
AD  - Department of Medical Laboratory Science and Biotechnology, Kaohsiung Medical 
      University, Kaohsiung 80708, Taiwan.
FAU - Hsieh, Feng-Ching
AU  - Hsieh FC
AD  - Larmood Company Limited, Pingtung 90076, Taiwan.
FAU - Wu, Tai-Yun
AU  - Wu TY
AD  - Department of General Medicine, Tri-Service General Hospital, National Defense 
      Medical Center, Taipei 11466, Taiwan.
FAU - Fang, Ai-Hui
AU  - Fang AH
AD  - Department of Microbiology, College of Medicine, Kaohsiung Medical University, 
      Kaohsiung 80708, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20230418
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC10129431
COIS- Hsieh FC is the President and Director of R&D of Larmood Company Limited. LPLM141 
      was obtained from Larmood Company Limited. The other authors declare that they 
      have no conflicts of interest.
EDAT- 2023/04/28 06:41
MHDA- 2023/04/28 06:42
PMCR- 2023/04/18
CRDT- 2023/04/28 02:39
PHST- 2022/04/22 00:00 [received]
PHST- 2023/03/10 00:00 [revised]
PHST- 2023/03/18 00:00 [accepted]
PHST- 2023/04/28 06:42 [medline]
PHST- 2023/04/28 06:41 [pubmed]
PHST- 2023/04/28 02:39 [entrez]
PHST- 2023/04/18 00:00 [pmc-release]
AID - 10.1155/2023/1011591 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2023 Apr 18;2023:1011591. doi: 
      10.1155/2023/1011591. eCollection 2023.